Sign Out
Daclatasvir in combination with peginterferon alfa and ribavirin: The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza-like illness, nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability, cough, diarrhoea, dyspnoea and arthralgia.
Tabulated list of adverse reactions: Adverse reactions are listed in Table 13 by regimen, system organ class and frequency: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. (See Table 13.)
Click on icon to see table/diagram/imageLaboratory abnormalities.
Description of selected adverse reactions: Cardiac arrhythmias: Cases of severe bradycardia and heart block have been observed when Daclatasvir is used in combination with sofosbuvir and concomitant amiodarone and/or other drugs that lower heart rate (see Precautions and Interactions).
Paediatric population: The safety and efficacy of Daclatasvir in children and adolescents aged <18 years have not yet been established. No data available.
View ADR Monitoring Form
